Diagnostics
Digital rectal examination cited as barrier to prostate cancer screening
Published in Clinical Oncology Week, November 21st, 2005
"[Our goal was] to determine whether use of the DRE results in decreased participation in prostate cancer (PCa) screening, which, in turn, would result in lower detection. Population based PCa screening includes prostate-specific antigen (PSA) measurement with or without a DRE. PSA and DRE screening provide greater sensitivity than PSA alone; however, the increased participation rate resulting from PSA-alone screening may result in a greater detection rate," scientists writing in the journal Urology reported.
"We performed a survey...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Cancer Therapy
Progressive muscle relaxation training reduced chemotherapy side effects - Palliative Care
Methotrimeprazine used in management of nausea and vomiting in advanced cancer - Prognostics
Age and race should not be used as factors in prostate cancer treatment decision-making - Prognostics
Circulating plasma cells predicted survival in patients with newly diagnosed multiple myeloma - Acute Myeloid Leukemia
Phase II study to evaluate Xanafide in combination with ara-C for secondary AML - Apoptosis
Accumulation of p53 sensitizes human cells to tumor necrosis factor alpha-induced apoptosis - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
